Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients

Kidney International

Volumn 62, Issue 6, 2002, Pages 2167-2175

  Vanrenterghem, Yves ^a,b,c,d,e   Bárány, Peter ^a,b,c,d,e   Mann, Johannes F E ^a,b,c,d,e   Kerr, Peter G ^a,b,c,d,e   Wilson, Janet ^a,b,c,d,e   Baker, Nigel F ^a,b,c,d,e   Gray, Stephen J ^a,b,c,d,e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Klinikum Schwabing   (Germany)

^d MONASH MEDICAL CENTRE   (Australia)

^e AMGEN LTD   (United Kingdom)

Author keywords

Anemia; Chronic renal failure; Darbepoetin alfa; Hemodialysis; Novel erythropoiesis stimulating protein (NESP); Peritoneal dialysis; Recombinant human erythropoietin

Indexed keywords

ANTIBODY; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; DRUG DERIVATIVE; ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG SAFETY; EUROPE; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TITRIMETRY; ADOLESCENT; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; MIDDLE AGED; MULTICENTER STUDY; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 0036436322     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00657.x     Document Type: Article

References (22)

1. Caro J, Brown S, Miller O, et al: Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93:449-458, 1979
2. Winearls CG, Oliver DO, Pippard MJ, et al: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet I:1175-1178, 1986
3. Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316:73-78, 1987
4. Faulds D, Sorkin EM: Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs 38:863-899, 1989
5. Cazzola M, Mercuriali F, Brugnara C: Use of recombinant human erythropoietin outside the setting of uremia. Blood 89: 4248-4267, 1997
6. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure: European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 14(Suppl 5):1-50, 1999
7. Besarab A, Flaharty KK, Erslev AJ, et al: Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol 2:1405-1416, 1992
8. Macdougall IC, Roberts DE, Neubert P, et al: Pharmacokinetics of intravenous, intraperitoneal and subcutaneous recombinant erythropoietin in patients on CAPD. Contrib Nephrol 76:112-121, 1989
9. Egrie JC, Browne JK: Development and characterisation of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84(Suppl 1):3-10, 2001
10. Macdougall IC, Gray SJ, Elston O, et al: Pharmacokinetics of novel erythropoiesis stimulating protein compared with Epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392-2395, 1999
11. Macdougall IC: Novel erythropoiesis stimulating protein. Semin Nephrol 20:375-381, 2000
12. Jones B, Jarvis P, Lewis JA, Ebbutt AF: Trials to assess equivalence: The importance of rigorous methods. BMJ 313:36-39, 1996
13. Uehlinger DE, Gotch FA, Sheiner LB: A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51:76-89, 1992
14. Eschbach JW, Abdulhadi MH, Browne JK, et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Int Med 111:992-1000, 1989
15. Weiss LG, Clyne N, Divino Fihlho J, et al: The efficiency of once weekly compared with two and three times weekly subcutaneous Epoetin beta: Results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 15:2014-2019, 2000
16. The CARI Guidelines (Caring for Australians with Renal Impairment). Australian Kidney Foundation and Australia New Zealand Society of Nephrology, 2001, Web site: http://www.cari.kidney.org.au
17. Churchill DN, Taylor DW, Cook RJ, et al: Canadian hemodialysis morbidity study. Am J Kidney Dis 19:214-234, 1992
18. Locatelli F, Bommer J, London GM, et al: Cardiovascular disease determinants in chronic renal failure: Clinical approach and treatment. Nephrol Dial Transplant 16:459-468, 2001
19. Pastan S, Bailey J: Medical progress: Dialysis therapy. N Engl J Med 338:1428-1437, 1998
20. Berthoux F, Jones E, Gellert R, et al: Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: Report of the European renal association registry and the national registries. Nephrol Dial Transplant 14:2332-2342, 1999
21. Nissenson AR, Swan SK, Lindberg JS, et al: Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40:110-118, 2002
22. Locatelli F, Olivares J, Walker R, et al: Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. European/Australian NESP 980202 Study Group. Kidney Int 60:741-747, 2001